PDT Partners LLC Purchases Shares of 63,859 ADMA Biologics, Inc. (NASDAQ:ADMA)

PDT Partners LLC acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, Holdings Channel.com reports. The firm acquired 63,859 shares of the biotechnology company’s stock, valued at approximately $1,277,000.

Several other institutional investors have also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co grew its position in ADMA Biologics by 114.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock valued at $357,000 after acquiring an additional 28,832 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of ADMA Biologics by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 60,924 shares of the biotechnology company’s stock valued at $403,000 after purchasing an additional 7,450 shares during the last quarter. CWM LLC raised its position in ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. SG Americas Securities LLC lifted its stake in ADMA Biologics by 3,084.6% in the second quarter. SG Americas Securities LLC now owns 363,742 shares of the biotechnology company’s stock worth $4,067,000 after purchasing an additional 352,320 shares during the last quarter. Finally, Roman Butler Fullerton & Co. purchased a new stake in ADMA Biologics during the second quarter valued at about $378,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 7.9 %

NASDAQ ADMA opened at $20.11 on Monday. The stock has a market cap of $4.75 billion, a P/E ratio of 71.82 and a beta of 0.64. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The stock has a 50 day simple moving average of $19.08 and a two-hundred day simple moving average of $15.40. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter last year, the firm posted $0.01 earnings per share. On average, analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analyst Ratings Changes

ADMA has been the topic of several analyst reports. Raymond James lifted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.